Back to results
US 2006/0189689 A1Published application
Arginine mimetics as factor Xa inhibitors
AssigneeWilex AG
InventorsLuis Moroder, Stefan Sperl, Jorg Sturzebecher
Life of this patent
Estimating the term…
Abstract
The invention relates generally to a novel type of arginine mimetics which are inhibitors of factor Xa; to pharmaceutical compositions which comprise these mimetics; and to the use of these arginine mimetics for producing compositions for antithrombotic therapy.
Claims8
A process for preparing a compound in accordance with the following structural formula:
- in which:
- R1 comprises a linker L1, which is directly bonded to the phenylalanine analog and which is selected from a bond, a group RX having a chain length of from 1 to 10 atoms, —CO—, —CO—NH—, —COO—, —CS—, —CS—NH—, —COS—, —CO—CH2—NH— or a natural or unnatural amino acid, and a substituted or unsubstituted, saturated or unsaturated, group R4;
- R2 comprises a linker L2, which is bonded directly to the phenylalanine analog, and which is selected from —OR5—, —NH—R5—, —NH—NH—R5— or —CH2—R5-where R5 can be a substituted or unsubstituted, saturated or unsaturated, carbocyclic, heterocyclic or noncyclic alkyl radical or a group RX, and a substituted or unsubstituted, saturated or unsaturated group R7;
- and
- R3 is a basic substituent at the 3 or 4 position of the aromatic ring of the phenylalanine radical and the aromatic ring is optionally substituted by additional substituents RY, in particular polar substituents and/or basic substituents and/or basic substituents, with z being=0 to 4, said process comprising:
- a) adding R4—NCO, R4—NCS, X—CO—R4, X-SO2-R4, X—CO—NH—R4 or X—COOR4 to D- or L-phenylalanine which, at the 3 or 4 position, possesses the basic substituent R3, or a precursor of R3;
- b) optionally converting the precursor of R3 into the substituent R3;
- and
- c) optionally adding YR5 to the reaction product of step b).
6 more elements
The use of a compound in accordance with the following structural formula:
- in which:
- R1 comprises a linker L1, which is directly bonded to the phenylalanine analog and which is selected from a bond, a group RX having a chain length of from 1 to 10 atoms, —CO—, —CO—NH—, —COO—, —CS—, —CS—NH—, —COS—, —CO—CH2—NH— or a natural or unnatural amino acid, and a substituted or unsubstituted, saturated or unsaturated, group R4;
- R2 comprises a linker L2, which is bonded directly to the phenylalanine analog, and which is selected from —OR5—, —NH—R5—, —NH—NH—R5— or —CH2—R5-where R5 can be a substituted or unsubstituted, saturated or unsaturated, carbocyclic, heterocyclic or noncyclic alkyl radical or a group RX, and a substituted or unsubstituted, saturated or unsaturated group R7;
- and
- R3 is a basic substituent at the 3 or 4 position of the aromatic ring of the phenylalanine radical and the aromatic ring is optionally substituted by additional substituents RY, in particular polar substituents and/or basic substituents and/or basic substituents, with z being =0 to 4, for producing a composition for anticoagulatory therapy.
2 more elements
The use of a compound in accordance with the following structural formula:
- in which:
- R1 comprises a linker L1, which is directly bonded to the phenylalanine analog and which is selected from a bond, a group RX having a chain length of from 1 to 10 atoms, —CO—, —CO—NH—, —COO—, —CS—, —CS—NH—, —COS—, —CO—CH2—NH— or a natural or unnatural amino acid, and a substituted or unsubstituted, saturated or unsaturated, group R4;
- R2 comprises a linker L2, which is bonded directly to the phenylalanine analog, and which is selected from —OR5—, —NH—R5—, —NH—NH—R5— or —CH2—R5-where R5 can be a substituted or unsubstituted, saturated or unsaturated, carbocyclic, heterocyclic or noncyclic alkyl radical or a group RX, and a substituted or unsubstituted, saturated or unsaturated group R7;
- and
- R3 is a basic substituent at the 3 or 4 position of the aromatic ring of the phenylalanine radical and the aromatic ring is optionally substituted by additional substituents RY, in particular polar substituents and/or basic substituents and/or basic substituents, with z being =0 to 4,
- for producing an antitumor composition.
3 more elements
The use of a compound in accordance with the following structural formula:
- in which:
- R1 comprises a linker L1, which is directly bonded to the phenylalanine analog and which is selected from a bond, a group RX having a chain length of from 1 to 10 atoms, —CO—, —CO—NH—, —COO—, —CS—, —CS—NH—, —COS—, —CO—CH2—NH— or a natural or unnatural amino acid, and a substituted or unsubstituted, saturated or unsaturated, group R4;
- R2 comprises a linker L2, which is bonded directly to the phenylalanine analog, and which is selected from —OR5—, —NH—R5—, —NH—NH—R5— or —CH2—R5-where R5 can be a substituted or unsubstituted, saturated or unsaturated, carbocyclic, heterocyclic or noncyclic alkyl radical or a group RX, and a substituted or unsubstituted, saturated or unsaturated group R7;
- and
- R3 is a basic substituent at the 3 or 4 position of the aromatic ring of the phenylalanine radical and the aromatic ring is optionally substituted by additional substituents RY, in particular polar substituents and/or basic substituents and/or basic substituents, with z being =0 to 4, as a diagnostic agent.
2 more elements
Dependencies are inferred from the claim text.